News Releases

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022

April 6, 2022

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

March 30, 2022

Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC

March 17, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

January 25, 2022

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

January 24, 2022

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

December 16, 2021

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

December 7, 2021

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

October 26, 2021

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

October 6, 2021

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

October 1, 2021

Latest News & Events

Mar 25, 2025

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Read More...

Mar 24, 2025

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Read More...

Mar 17, 2025

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Read More...